Audentes Therapeutics is now Astellas Gene Therapies. Read our Press Release and visit www.astellas.com to learn more.

Team
Our Approach
Innovative Therapies
Careers
News
Contact
Patients + Families

Home
News

News

Jul 26, 2022

Astellas Unveils Plans to Open New Biotech Campus in South San Francisco

Jun 08, 2022

Astellas Celebrates the Opening of Its New Large-Scale Gene Therapy Manufacturing Facility in North Carolina

Apr 22, 2022

Notice Regarding Impairment Loss for Products under Development

Feb 07, 2022

Astellas Announces Positive Safety Data from the FORTIS Study of AT845 in Adults with Late-Onset Pompe Disease

Dec 02, 2021

Astellas and Dyno Therapeutics Announce Research Collaboration to Develop Next-Generation AAV Gene Therapy Vectors for Skeletal and Cardiac Muscle

Sep 14, 2021

Astellas Reports Update to Sept. 1 Announcement on the ASPIRO Clinical Trial of AT132 in Patients with X-linked Myotubular Myopathy

Sep 01, 2021

Astellas Provides Update on ASPIRO Clinical Trial of AT132 in Patients with X-linked Myotubular Myopathy

Mar 31, 2021

Audentes Therapeutics Expands Mission, Becomes Astellas Gene Therapies

Dec 24, 2020

Audentes Therapeutics Announces FDA Lifts Hold on ASPIRO Clinical Trial of AT132 for Treatment of X-Linked Myotubular Myopathy (XLMTM)

Pagination

Current page 1
Page 2
Next page
Last page

Footer Menu 1

TEAM
OUR APPROACH

Footer Menu 2

INNOVATIVE THERAPIES

Footer Menu 3

CAREERS
NEWS
CONTACT
PATIENTS + FAMILIES
US PRIVACY POLICY
EU PRIVACY POLICY

600 California Street, 17th Floor
San Francisco, CA 94108
Phone: (415) 818-1001
Email: [email protected]

© Copyright 2022 Audentes Therapeutics. Terms and Conditions | Privacy Statement

back to top